British Association of Dermatologists and British Photodermatology Group Guidelines for the Safe and Effective Use of Psoralen–Ultraviolet A Therapy 2015

T.C. Ling; T.H. Clayton; J. Crawley; L.S. Exton; V. Goulden; S. Ibbotson; K. McKenna; M.F. Mohd Mustapa; L.E. Rhodes; R. Sarkany; R.S. Dawe

Disclosures

The British Journal of Dermatology. 2016;174(1):24-55. 

In This Article

Recommended Audit Points

Is there a system in place to record and recall episodes of 'burning' which clearly:

  1. Grades each episode;

  2. Reviews all episodes at 6-monthly intervals;

  3. Interprets the result in the context of the total number of treatments and total number of patients treated?

Over the last 12 months:

  1. Was there clear documentation of instances of painful erythema?

  2. Was there clear documentation of staff training records for topical and/or oral PUVA therapy?

  3. Was a patient information leaflet provided to (i) the last 20 consecutive patients receiving topical PUVA therapy; (ii) the last 50 consecutive patients receiving oral PUVA therapy?

  4. Was there clear documentation on advising patients on the risk of skin carcinogenicity on sun-exposed skin for (i) the last 20 consecutive patients receiving topical PUVA therapy; (ii) the last 50 consecutive patients receiving oral PUVA therapy?

  5. Was there clear documentation on advising patients on eye protection and UV protection following each oral PUVA treatment for the last 50 consecutive patients?

The audit recommendation of 20 or 50 cases per department is to reduce variation in the results due to a single patient, and to allow for benchmarking between different units. However, departments unable to achieve this recommendation may choose to audit all cases seen in the preceding 12 months.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....